

CORRECTION

Open Access



# Correction to: Roles of Rufy3 in experimental subarachnoid hemorrhage-induced early brain injury via accelerating neuronal axon repair and synaptic plasticity

Yang Wang<sup>1,2†</sup>, Jianguo Xu<sup>1†</sup>, Wanchun You<sup>1</sup>, Haitao Shen<sup>1</sup>, Xiang Li<sup>1</sup>, Zhengquan Yu<sup>1\*</sup>, Haiying Li<sup>1\*</sup> and Gang Chen<sup>1</sup>

**Correction to: Mol Brain 15, 35 (2022).**

<https://doi.org/10.1186/s13041-022-00919-6>

Following publication of the original article [1], the authors identified two errors in the Figs. 4e and 8b. Specifically, the amplification area of SAH + LV-Rufy3 group in the Fig. 4e and the amplification area of SAH + LV-NC1 group in the Fig. 8b were incorrect. The other elements of the figure remain unchanged.

In addition, there are two mistakes in the Figure caption of Figs. 4 and 6. Specifically, the description of  $\beta$ -tubulin III (NeuN; red, Alexa Fluor 555) should instead read as  $\beta$ -tubulin III (axon; red, Alexa Fluor 555).

These changes do not affect the results or conclusions of this study.

The authors apologize for any inconvenience caused.

The incorrect and correct Figs. 4, 6 and 8 are indicated hereafter.

<sup>†</sup>Yang Wang and Jianguo Xu contributed equally to this work.

The online version of the original article can be found at <https://doi.org/10.1186/s13041-022-00919-6>.

\*Correspondence:


Zhengquan Yu  
ahsz\_neurosurgery@163.com  
Haiying Li  
lhy1015@suda.edu.cn

<sup>1</sup>Department of Neurosurgery & Brain and Nerve Research Laboratory, The First Affiliated Hospital of Soochow University, 188 Shizi Street, Suzhou, Jiangsu 215006, China

<sup>2</sup>Department of Neurosurgery, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, China




The incorrect Fig. 4 (caption):




**Fig. 4** The protein expression levels of Rufy3 and the state of neuronal axon under LV-shRNA and LV-Rufy3 treatments after vivo and vitro SAH. **a** Representative bands of Rufy3 detected by western blot under 8p-CPT, LV-shRNA and LV-Rufy3 treatments following vivo SAH. **b** Representative bands of Rufy3 detected by western blot under LV-shRNA and LV-Rufy3 treatments following vitro SAH. **c, d** Quantitative analysis of Rufy3 in different groups following vivo and vitro SAH. The sham and control group were used as a control. **e** Double immunofluorescence analysis of Rufy3 (green, Alexa Fluor 488) and  $\beta$ -tubulin III (NeuN; red, Alexa Fluor 555); nuclei were stained with DAPI (blue). Scale bars = 32  $\mu$ m. **f, g** Quantitative fluorescent intensity analysis of Rufy3 and  $\beta$ -tubulin III expressions in different groups. The sham group was used as the standard. **h** Quantitative analysis of the length of neuronal axon in different groups. **i** Double immunofluorescence of Rufy3 (green, Alexa Fluor 488) and  $\beta$ -tubulin III (axon; red, Alexa Fluor 555). Nuclei were stained with DAPI (blue). Scale bars = 100  $\mu$ m. Data are shown as mean  $\pm$  SEM ( $n=6$ ).  $^{*}P<0.01$ ,  $^{**}P<0.001$  vs. Sham group;  $^{\#}P<0.05$ ,  $^{\#\#}P<0.01$  vs. LV-NC1 groups;  $^{\&}P<0.05$ ,  $^{\&\&}P<0.01$ ,  $^{\&\&\&}P<0.001$  vs. LV-NC2 group;  $^{\$}P<0.05$  vs. LV-Rufy3 group

The correct Fig. 4 (caption):




**Fig. 4** The protein expression levels of Rufy3 and the state of neuronal axon under LV-shRNA and LV-Rufy3 treatments after vivo and vitro SAH. **a** Representative bands of Rufy3 detected by western blot under 8p-CPT, LV-shRNA and LV-Rufy3 treatments following vivo SAH. **b** Representative bands of Rufy3 detected by western blot under LV-shRNA and LV-Rufy3 treatments following vitro SAH. **c, d** Quantitative analysis of Rufy3 in different groups following vivo and vitro SAH. The sham and control group were used as a control. **e** Double immunofluorescence analysis of Rufy3 (green, Alexa Fluor 488) and  $\beta$ -tubulin III (axon; red, Alexa Fluor 555); nuclei were stained with DAPI (blue). Scale bars = 32  $\mu$ m. **f, g** Quantitative fluorescent intensity analysis of Rufy3 and  $\beta$ -tubulin III expressions in different groups. The sham group was used as the standard. **h** Quantitative analysis of the length of neuronal axon in different groups. **i** Double immunofluorescence of Rufy3 (green, Alexa Fluor 488) and  $\beta$ -tubulin III (axon; red, Alexa Fluor 555). Nuclei were stained with DAPI (blue). Scale bars = 100  $\mu$ m. Data are shown as mean  $\pm$  SEM ( $n=6$ ). \* $P < 0.01$ , \*\* $P < 0.001$  vs. Sham group; # $P < 0.05$ , ## $P < 0.01$  vs. LV-NC1 groups; &#amp;#amp; $P < 0.05$ , &#amp;#amp; $P < 0.01$ , &#amp;#amp; $P < 0.001$  vs. LV-NC2 group; \$ $P < 0.05$  vs. LV-Rufy3 group

The incorrect Fig. 6 (caption):




**Fig. 6** Effects of LV-shRNA and LV-Rufy3 on the Rap1/Arap3/Rho/Fascin signaling axis after experimental SAH. **a** Representative bands of Fascin and Facin expressions. **b, c** Quantitative analysis of Fascin and Facin. The sham group was used as control. **d** Representative bands of Arap3 and Rho expressions. **e, f** Quantitative analysis of Arap3 and Rho. The sham group was used as control. **g** Double immunofluorescence of Fascin (green, Alexa Fluor 488) and β-tubulin III (NeuN; red, Alexa Fluor 555); nuclei were stained with DAPI (blue). Scale bars = 40 μm. **h, i** Quantitative fluorescent intensity analysis of Rufy3 and β-tubulin III expressions in different groups. The sham group was used as the standard. **j** Quantitative analysis of the length of neuronal axons in different groups. \**P* < 0.05, \*\**P* < 0.01, \*\*\**P* < 0.001 vs. Sham group; #*P* < 0.05, ##*P* < 0.01 vs. LV-NC1 groups; &*P* < 0.05, &&*P* < 0.01, &&&*P* < 0.001 vs. LV-NC2 group; §*P* < 0.05 vs. LV-Rufy3 group

The correct Fig. 6:




**Fig. 6** Effects of LV-shRNA and LV-Rufy3 on the Rap1/Arap3/Rho/Fascin signaling axis after experimental SAH. **a** Representative bands of Fascin and Facin expressions. **b, c** Quantitative analysis of Fascin and Facin. The sham group was used as control. **d** Representative bands of ARAP3 and Rho expressions. **e, f** Quantitative analysis of ARAP3 and Rho. The sham group was used as control. **g** Double immunofluorescence of Fascin (green, Alexa Fluor 488) and β-tubulin III (axon; red, Alexa Fluor 555); nuclei were stained with DAPI (blue). Scale bars = 40 μm. **h, i** Quantitative fluorescent intensity analysis of Rufy3 and β-tubulin III expressions in different groups. The sham group was used as the standard. **j** Quantitative analysis of the length of neuronal axons in different groups. \* $P < 0.05$ , \*\* $P < 0.01$ , \*\*\* $P < 0.001$  vs. Sham group; # $P < 0.05$ , ## $P < 0.01$  vs. LV-NC1 groups; & $P < 0.05$ , && $P < 0.01$ , &&& $P < 0.001$  vs. LV-NC2 group; § $P < 0.05$  vs. LV-Rufy3 group

The incorrect Fig. 8:



**Fig. 8** Effect of LV-shRNA and LV-Rufy3 on cortical cell apoptosis and degradation, brain edema, and neurological score after SAH. **a** Double immunofluorescence analysis of TUNEL staining (red, Alexa Fluor 555) and neuronal marker (NeuN; green, Alexa Fluor 488) was performed to assess neuronal apoptosis at 24 h after SAH. **b** Fluoro-Jade C staining (green) was performed to evaluate neuronal degeneration and arrows pointed to FJC-positive cells. **c** Quantitative analysis of apoptotic neuron percentage. **d** Quantitative analysis of Fluoro-Jade C positive cells/mm<sup>2</sup> in brain sections in each group. **e** Double immunofluorescence of MBP (green, Alexa Fluor 488) and neuronal marker (NeuN; red, Alexa Fluor 555), and Rufy3 mainly located in the neurons. **f** Brain water content. **g** Neurological scoring. Scale bars = 100  $\mu$ m. \*\*\* $P$  < 0.001 vs. Sham group; # $P$  < 0.05, ## $P$  < 0.01, ### $P$  < 0.001 vs. LV-NC1 groups;  $^{\&}$  $P$  < 0.05,  $^{\&&}$  $P$  < 0.001 vs. LV-NC2 group;  $^{\$}$  $P$  < 0.05,  $^{\$ \$}$  $P$  < 0.001 vs. LV-Rufy3 group

The correct Fig. 8:



Figures 4, 6 and 8 have been updated above and the original article [1] has been corrected.

### Publisher's note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Published online: 14 January 2025

### References

1. Wang Y, Xu J, You W, et al. Roles of Rufy3 in experimental subarachnoid hemorrhage-induced early brain injury via accelerating neuronal axon repair and synaptic plasticity. *Mol Brain*. 2022;15:35. <https://doi.org/10.1186/s13041-022-00919-6>.